New Short-Course malaria treatment could prevent relapses

NCT ID NCT05874271

Completed Disease control Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new approach to treat vivax malaria, a type that can hide in the liver and come back. Researchers used a quick test to check for a genetic condition (G6PD deficiency) that can cause dangerous side effects with the standard drug primaquine. Then, they gave a high-dose, short-course primaquine regimen tailored to each patient's G6PD level. The goal was to see if this strategy is safe, practical, and effective in preventing malaria relapse. The study involved 794 patients in Papua New Guinea.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: primaquine
What this could lead to: If successful, this approach could make radical cure of vivax malaria safer and more practical, reducing relapses and helping control the disease in affected regions.
What could go wrong: This is a feasibility study, not a large randomized trial, so results may not be definitive. The risk of hemolysis in G6PD-deficient patients remains a concern despite testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for G6PD DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

G6PD deficiency Plasmodium vivax malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

G6PD DEFICIENCY VIVAX MALARIA

Contacts and locations

Locations

Baro Clinic

Vanimo, Sandaun Province, Papua New Guinea
Mugil Health Centre

Madang, Madang Province, Papua New Guinea
Napapar Health Centre

Kokopo, East New Britain Province, Papua New Guinea
Wirui Clinic

Wewak, East Sepik Province, Papua New Guinea

More trials for these conditions

Other studies related to the condition(s) this trial covers.